A few of us have talked about Trillium Therapeutics before as an example of a very well managed biotech company.  Lead by a proven, real biotech professional.  It's lead drugs are early clinical stage cancer therapeutics in the CD47 space and today it was purchased by Pfizer for $2.26B USD or $18.60USD/share.  I am a very happy TRIL shareholder today!

When Jan Skvarka stepped in as CEO in late 2019 the shares were trading below $.40USD, the company was reorganizing and had in its recent past taken new direction in its science. Excellent science and excellent management can effect positive change fairly quickly. I think the Zenith science is proving to be in the excellence category and except in the CEO chair there seem to be some good business minds at Zenith. The board is also very weak in terms of biotech business success.  Despite the deficiencies in leadership hopefully shareholders will be rewarded at some point soon with a result at least similar to Trillium or Constellation.